Clinical trial

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

NCT00412412

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-12-01

PhasePHASE1

Study timeline

Study start (unknown)2007-12-01Date precision: month

Registry last updated2012-06-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

CNF2024DRUG

CNF2024 + trastuzumabDRUG

Sponsors & collaborators

Biogenlead sponsor

Mapped research locations

New YorkNew York, United States1 HoustonTexas, United States1 TampaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00412412 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.